In this article
FDA Approval of Pembrolizumab for Biliary Tract Cancer
On October 31, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin to treat biliary tract carcinoma (BTC) that has spread or is locally advanced but can not be removed.
KEYNOTE-966 Clinical Trial and Efficacy Results
The effectiveness was assessed in a study called KEYNOTE-966 (NCT04003636), which was a multicenter, randomized, double-blind, placebo-controlled trial involving 1069 patients with locally advanced unresectable or metastatic BTC who had not undergone previous systemic therapy for advanced illness. Patients were randomly assigned to receive either pembrolizumab in combination with gemcitabine and cisplatin every 3 weeks or a placebo in combination with gemcitabine and cisplatin on the same schedule. Treatment persisted until intolerable side effects or advancement of the disease. Cisplatin was given for up to 8 cycles, whereas gemcitabine was continued based on the physician’s judgment. The administration of pembrolizumab or placebo was maintained until illness progression, intolerable toxicity, or a maximum duration of 2 years.
The primary effectiveness endpoint was overall survival (OS). Pembrolizumab combined with chemotherapy showed a substantial increase in overall survival compared to placebo combined with chemotherapy, with a hazard ratio of 0.83 (95% CI: 0.72, 0.95); one-sided p-value=0.0034. The median overall survival (OS) was 12.7 months with a 95% confidence interval (CI) of 11.5 to 13.6 in one group and 10.9 months with a 95% CI of 9.9 to 11.6 in the other group.
Side Effects and Adverse Events Management
Interruption of pembrolizumab due to adverse events occurred in 55% of patients. Low neutrophil count, low platelet count, anemia, low white blood cell count, fever, tiredness, cholangitis, elevated ALT and AST, and biliary obstruction were some of the side effects or lab problems that happened so often (≥2%) that the treatment had to be stopped.
Recommended Dosage and Administration for Keytruda
The suggested dosage of pembrolizumab is 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression or intolerable toxicity. Administer pembrolizumab before chemotherapy if both are given on the same day.
View full prescribing information for Keytruda.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Related Articles
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.